Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Senzagen AB is a biotech company that specializes in developing innovative non-animal test methods for assessing chemical safety. The primary function of Senzagen is to provide alternative testing solutions that replace traditional animal testing in the cosmetics, pharmaceutical, and chemical industries. The company's flagship product, GARD (Genomic Allergen Rapid Detection), uses genomics technology to deliver precise and reliable results for skin sensitization tests. With a strong focus on sustainability and ethics, Senzagen's methods are designed to meet regulatory and consumer demands for cruelty-free testing practices. By employing proprietary genomic technologies, the company ensures high accuracy and reproducibility in testing, offering a humane and effective alternative to animal testing. Senzagen's solutions have gained traction in Europe and globally, reflecting a shift towards ethical testing methods across the industry. The company plays a critical role within the biotech sphere, influencing how safety assessments are conducted in various sectors, and marking significant progress in achieving the EU's vision for a future without animal testing. Headquartered in Lund, Sweden, Senzagen is at the forefront of redefining standards in chemical safety evaluations.
kr 0.48
kr 0.01 (-1.04%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-19.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 0.5%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -kr 12M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 59M
▲ +0.5% YoY
Net Income (TTM)
-kr 14M
▲ +35.1% YoY
Op. Margin
-17.98%
▼ -0.6pp YoY
ROIC
-9.40%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 15M
▲ +11.2% YoY
Op. Cash Flow (TTM)
-kr 13M
▲ +29.6% YoY
Net Debt
-kr 8M
Net Cash Position
Cash & Equiv.
kr 27M
3Y CAGR: +11.5%
Continue Research
Senzagen AB (SENZA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Senzagen AB scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Senzagen AB scores 36 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -18.0% operating margin and a -9.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SENZA.XSTO's valuation and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.